BriaCell Therapeutics (BCTX) said Wednesday that a phase 2 study of its Bria-IMT regimen with check point inhibitors to treat metastatic breast cancer showed positive survival results.
The study showed a median survival of 17.3 months in certain patients, surpassing the 14.4 months seen for the antibody-drug conjugate treatment Trodelvy, the company said .
For triple-negative breast cancer, the company said Bria-IMT showed survival comparable to Trodelvy but significantly better than chemotherapy, with a 70% improvement.
The drug developer said it plans to further evaluate the results in an ongoing phase 3 trial focused on overall survival.
BriaCell shares rose 27% in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.